chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Before the vaccine, I was able to and hold down food. After words, my throat was irritated and I kept throwing up due to that feeling. It's been going on for close to over a month and I'm currently taking Acid Reflux medication, Vomiting and Nausea medication after going to the a gastroenterologist to which they didn't find anything doing an endoscopy that occurred on April 12th, 2021. Still waiting on the biopsy. With medication, current only symptom is painful stool (due to medication most likely) and after eating, burning in the throat (most likely due to acid reflux type symptoms). Only able to eat a certain amount before throwing up again.
On the night of the day I received the shot, I ran a fever. For the next two days, I had fatigue and a fever. Temperature was generally between 100 and 101.9.  My normal temperature is 97.6.  For the next 2 days, I had no fever but did have fatigue.
A non-serious spontaneous report of administered expired FLUMIST was received from a health professional concerning a 36-month-old female. Neither relevant medical history nor concomitant medications have been reported for this patient. The product expired on 04-Mar-2012. On 09-Mar-2012, the patient received expired product. There was no adverse event associated with this medication error; therefore, treatment and reporter causality assessments are not applicable, and the event is considered resolved. This case will be submitted in accordance with MedImmune FLUMIST post-marketing commitment for the indicated population of 2 years to 59 months of age. Additional information was received on 16-Apr-2012: No late occurring adverse events were reported.
1st Shingrex vaccine - 3-29-2022 - Severe recurrence of HSV1 (genital) after 30 years of no recurrence.  I was told that it was not from the vaccine, as it occurred several weeks after the vaccine. Diagnosis with a lab test and prescription for Valcyclovir   2nd Shingrex vaccine - 3-23-2022 - Another recurrence  of HSV1 (genital, not quite as serious) two days after the vaccination. Prescription for Valcyclovir called in by MD
Headache, Myalgia, Arthralgia, NauseaVomiting, SWOLLEN LYMPH NODES LEFT AXILLA, TENDERNESS AT INJECTION SITE, LEFT BREAST SORE Narrative:
Patient came to clinic, checked in at patient registration  patient received Vaccination, no Known side effects Director called  confirmed patient received Vaccination Provider  called parent New Preventive measures introduced
Information has been received from a physician via a company representative, referring on herself, a 61 year old patient. The patient's concurrent conditions and concomitant therapies were not reported. As medical history was reported drug reactions/allergies to penicillin (unspecified), aspirin (manufacturer unknown) and acetaminophen. On an unknown date in April 2017 (reported as in the "beginning of April" of this year (2017)), the patient was vaccinated with ZOSTAVAX, 0.65 ml, subcutaneously (strength, anatomical location, lot number and expiration date were not reported) and also received the sterile diluent (manufacturer unknown) subcutaneously (dose, anatomical location, lot number and expiration date were not reported) both products for shingles prevention. On an unspecified date in 2017,  after the patient received the ZOSTAVAX, she developed an allergic reaction that mainly consisted of symptoms where she had shortness of breath and difficulty breathing. It was confirmed that the patient did not seek medical attention, however she took an unspecified therapies as treatment for the adverse events. The outcome of the allergic reaction and the shortness of breath/difficulty breathing was reported as recovered and the causality between the events and the vaccination with ZOSTAVAX and the diluent (manufacturer unknown) was not reported. No product quality complaint (PQC) was involved. This is one of two reports received from the same patient. Additional information is not expected because there was no consent to contact for follow-up.; Sender's Comments: US-009507513-1705USA011368:
Severe arm soreness leading to Frozen Shoulder lasting for months.  Steroid shot and physical therapy needed.  Still symptomatic at this time.  This was on top of the fever, chills, nausea, and fatigue for three days.
Diagnosed with Gullian-Barre Syndrome after several weeks of progressive rapid loss of muscle function/peripheral neuropathy of limbs, trunk and head.
My patient received the Johnson and Johnson vaccine for SARS-Cov-2 on or about March 25, 2021. By mid June he started having weakness in his extremities. It first struck his lower extremities and then his upper extremities. His strength worsened day-by-day and he developed hypesthesia in the extremities. By early July he was so weak he could not rise from a chair and could not walk. He furthermore could not tolerate the pain because everything touching his skin, even clothing, was immensely painful. He was admitted to the hospital for a week. He did respond to glucocorticoid steroids but must continue taking them now in order to have strength and tolerate the discomfort. The problem has drastically changed his life and seems to be persistent. He has seen a neurologist at my request The patient's admission to the hospital. The chemistry and blood tests are available there.
sudden hypotonic episode @ home where pt suddenly appeared limp & unresponsive to parents lasted only a few minutes;VS S & pt alerty by the time ambulance arrived
Vaginal bleeding following the vaccine for 2 days; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 30-years-old non pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported), via an unspecified route of administration, administered in Arm Left on 21Jul2021 11:00 (at the age of 30-year-old) as dose 1, single for covid-19 immunisation. The patient medical history was not reported. Patient took Prenatal vitamins in two weeks. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 21Jul2021 18:00, the patient experienced vaginal bleeding following the vaccine for 2 days. No treatment was taken as a result of events. The outcome of the event was recovered on an unspecified date in Jul2021.   Information about lot/batch number cannot be obtained. No further information expected.
after administration patient complained of not feeling well. she passed out, face pale. I held her in the chair so she didn't fall out. Patient head rolled around and eyes rolled back in head. Technician came to assist the other half of her body so she didn't fall over. She turned red, jerked once and head/shoulders twitched.  Body was stiff and neck/head was tense, almost stuck. After coming back to, she complained of being hot, asked for water.  Sat for 2 minutes then patient insisted on leaving,  it was brought to attention that she had wet herself after she walked away.  I called her outside and asked how she was feeling. asked about seizure history. She said this has happened before in front of doctor and he did not mention seizure activity.
No additional AE; improperly stored vaccine; This spontaneous report was received from a healthcare professional and refers to a patient of unknown age and gender. No information regarding the patient's medical history, concurrent conditions or concomitant therapies was provided.  On 15-JUN-2022, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot #W002599, expiration date: 24-JAN-2024 (strength, exact dose and route of administration were not provided) for prophylaxis (Product storage error).  On an unknown date, before the administration, the vaccine underwent temperature excursion (missing information, clarification pending) at unknown conditions for an unknown period of time. No previous temperature excursions were reported. No adverse events were reported (No adverse event).
5/27/09 S.T. Congestion; 6/2/09 Fever, leg pain; 6/6/09 headache, vomiting; 6/10/09 - broad-based gait, facial weakness/? asymmetry.  7/21/09 Hospital records received 6/11/09 to 6/23/09. Assessment Post-viral cerebellar ataxia. Patient developed pharyngitis, fever, sinusitis. Severe headache, vomiting, fatigue, malaise. Evaluated at several other clinics, given antibiotics and IV fluids. Subsequently lost appetite, developed right facial swelling, difficulty eating, jaw pain, slurred speech, and a wide stance gait. Presented to the ER with ataxia, fatigue and malaise. Fever, throat pain, jaw pain, URI, vomiting, back and lower extremity pain and lethargy. Ill in appearance. Difficulty opening mouth. Difficulty swallowing. Wide based gait, difficulty tandem walking. Nosebleeds. Miller Fisher Syndrome?  ICD-9 Codes: 781.3  357.0  112.0  578.0  783.0  787.20  461.0  477.9  784.7
On 1/8/21 I had pain in my left ear and a feeling of fluid like an earache, also had a pressure type headache behind my eyes and felt fatigued. I stayed home from work and reported it and was told I could return to work on 1/11 (my next scheduled day) by workplace health. I felt fatigue and eye pressure headaches on and off since. I also felt like I was having vision changes. On 1/14/21 I noticed a small, raised, red area at the injection site. Over the weekend it continued to spread over my arm. It is warm and very mild tenderness to palpation but does not itch. I am also feeling tight muscle pain in my left shoulder and left side of my neck.
Patient was given his third Hep B dose only 4 weeks after second dose and it should have been 8 weeks.
Onset of dizziness & clamminess shortly after the shot.  No nausea.  No near syncope. He has had classic vasovagal events in the past including syncope atleast once.   He thought symptoms were similar but less intense than prior V-V events.     No CP, SOB, tingling. Initial BP - 132/90  P 97   O2 sat - 98% All VS remained stable throughout observation time. He felt better soon after lying down for a short time. No orthostasis occurred and he ambulated comfortably before D/C.
pt recvd vax on 9OCT95;mom reports rash on face & legs appeared in the evening of 9OCT95;took pt to clinic 9PM was advised to administer DPh; afeb w/sl red bumps
Presented to the ED due to shortness of breath and new onset fevers and chills.  Denies any chest pain, palpitations, coughing.  No exacerbating or alleviating factors.  ED workup significant HR max 130, RR max 28, positive COVID-19.  Elevated troponin 35 (this is at patient's baseline), with elevated BNP 4741.    Tested positive on 01/04/2022 Presented to the ED due to shortness of breath and new onset fevers and chills.  Denies any chest pain, palpitations, coughing.  No exacerbating or alleviating factors.  ED workup significant HR max 130, RR max 28, positive COVID-19.  Elevated troponin 35 (this is at patient's baseline), with elevated BNP 4741.   - EKG reveals atrial fibrillation with rapid ventricular response  - Chest x-ray reveals findings below  (01/04/2022 01:34 EST XR Chest 1V) 1.  Probable moderate to large bilateral pleural effusions.  2.  Bilateral perceived increased interstitial markings may suggest interstitial edema or atypical infectious/inflammatory process. [1]
Around 9, I came down with fever, aches, chills, that lasted through the night so I took and Advil at 1 am, then at noon I took another Advil. The aches and chills without Advil lasted for 2 nights. For a while I was fine but on 04/29/2021 I was having sharp pains in my gut that kept coming and going. I googled it and I thought it was my colitis or a blood clot. I went to the ER they did an CAT scan in my gut and they said it was definitely ulcerative colitis, which I have had for  years but without any flare ups for 21 years. They sent me to a GI doctor and they did a colonoscopy. They confirmed that it was colitis but not that severe and that I should be fine. After that I have been doing ok. I have had like two incidents since then but not as bad as the time I had to go to the ER.
Extreme pain started evening of injection, over night and following 2 days chills, aches, headache and arm pain worsen.  Gone in 2 full days after injection
I got dizzy after the Pfizer vaccine; This is a spontaneous report received from a contactable reporter (Consumer). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date 21Apr2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DIZZINESS (non-serious) with onset 2021, outcome "unknown", described as "I got dizzy after the Pfizer vaccine". Additional information:Patient got dizzy after the Pfizer vaccine, patient didn't realize it was a severe adverse reaction. This happened 11 days after patient got the vaccine. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Caller stated that patient had a stroke and is paralyzed on the left side of his body. He is getting a little feeling back in the left arm. He can move it, but he can not control it.
Pt almost fell off chair while getting Covid vaccination with syncope episode.  States has history of light headedness with vaccines.  Became pale, diaphoretic, blurry vision & muffled hearing.  Assisted to Observation area. BP 120/82 P64 R16  6:15P skin pink & warm, sitting up taking juice & crackers.   6:30P Released to mother.  Advised to take 2nd shot lying down.
three patient that received the second  booster to early; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (three patient that received the second  booster to early) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027L21A, 069H21A, 018B21A and 024M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-Apr-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-Apr-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (three patient that received the second booster to early). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (three patient that received the second booster to early) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medications were provided by the reporter.      No Treatment medications were provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 20-Apr-2022: Live Follow-up received contains No new information
The patient's lips were extremely swollen and was complaining about his hands feeling funny and they were red the night following vaccination. Patient also had hives, and his eyelids were swollen as well. The patient went to the ER. The patient was given Benadryl in the ER and was prescribed prednisone. Patient is on maintenance medications for chronic migraines. The course of the reaction was 3 days and patient is well.
This case was reported by a pharmacist and described the occurrence of fever in a child of unspecified gender who was vaccinated with diphtheria and tetanus toxoids and acellular pertussis vaccine (Dtpa, manufacturer unspecified) for prophylaxis. On an unspecified date on or before 19 May 2006, the subject received a dose of Dtpa (dose number and lot number not provided). At an unspecified time after vaccination with Dtpa, the subject experienced "high" fever and "excessive" crying. The subject was seen at physician's office. the outcome of the events was not reported. Report received via Merck & Co., Inc.
Initial unsolicited report received from a pharmacist on 1 June 2015. A 32-year-old female patient, with no medical history and concomitant medications were not reported, had received a dose of ADACEL (batch number- U5213BA, expiry date- 12 February 2017, route of administration was not reported) in left deltoid region on 28 May 2015. Patient had no illness at the time of vaccination. On 30 May 2015, 2 days after vaccination, the patient experienced red lump with pain at the injection site. No laboratory investigations were performed. Patient was advised ice treatment and rest for the arm. Patient required ER/doctor visit. At the time of this report, patient had not recovered from the event. Documents held by sender: none. Follow-up report received from a pharmacist on 18 August 2015. It was reported that the patient had received 0.5 ml intramuscular injection of ADACEL (expiry date 2 December 2017 previously reported as 12 February 2017) in left arm. The patient experienced event on 29 May 2015, one day after vaccination.
When administering a pfizer shot using a vanish point syringe, the syringe retracted and the liquid ran down the patient's arm instead of going into muscle. More than half the 0.3ml dose ran down the arm, so the shot was administered again with the 0.3ml dose with a new syringe in the same arm per patient's request.
3 days after receiving Pfizer vaccine. pt developed chest pain and shortness of breath. Seen at ER diagnosed as Pericarditis/Chest Wall Pain. Sent home on ibuprofen . Still having chest pain and shortness of breath. It has been 5 weeks per mom.
KINRIX given to 4 month old no symptoms indicated. Pt doing well. No treatment.
shooting left shoulder pain that has not improved since the vaccine. Pain affects activities like driving, sleeping, and he is unable to golf. Left arm with no swelling, redness, and is not tender to the touch, but patient reports pain with any mobility or certain positioning. Worst pain in 3-4 days post vaccination; really uncomfortable x next week and by 10/14 pain continues at moderate level
Nausea and cold chills starting morning of 2/20 lasting until 2/21. No treatment.
Patient experienced lightheadedness after vaccination and fell down. He was able to get up and sit on chair after 1 minute. We offered water, checked blood pressure (92/78). Ambulance arrived and patient went to hospital. Will follow up how he's doing later today.
Pt was here to recieve her 1st booster in the series from the 11 and under vial and pt recived 0.2 of the 12 and older vial
Rash in the injection site; itch in the injection site; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 18-Oct-2021 and was forwarded to Moderna on 18-Oct-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (Rash in the injection site) and PRURITUS (itch in the injection site) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026D21A and 058E21A) for COVID-19 vaccination.     No Medical History information was reported.   On 17-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Oct-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In October 2021, the patient experienced VACCINATION SITE RASH (Rash in the injection site) and PRURITUS (itch in the injection site). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) in October 2021 for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE RASH (Rash in the injection site) had not resolved and PRURITUS (itch in the injection site) outcome was unknown.            No concomitant medications were reported. Patient reports that she's experiencing Rash at the time of the report, i.e.,18-Oct-2021 and its not resolved. She took Benadryl and it helped her with the symptoms.   This case was linked to MOD-2021-355776 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 20-Oct-2021: Follow up received contains non-significant information.
Cardiac arrest; Blood clot in the lung; Incontinence; This spontaneous case was reported by a patient family member or friend and describes the occurrence of CARDIAC ARREST (Cardiac arrest) and PULMONARY EMBOLISM (Blood clot in the lung) in a male patient of an unknown age who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Concomitant products included HEPARIN for Thrombosis prophylaxis.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced CARDIAC ARREST (Cardiac arrest) (seriousness criteria death and medically significant), PULMONARY EMBOLISM (Blood clot in the lung) (seriousness criteria death and medically significant) and INCONTINENCE (Incontinence). The patient died on 19-Apr-2023. The reported cause of death was Cardiac arrest and blood clot in the lung. It is unknown if an autopsy was performed. At the time of death, INCONTINENCE (Incontinence) outcome was unknown.            On an unknown date, patient received Moderna COVID shots and boosters.   On an unknown date, patient went to hospital for incontinence and died on 19-Apr-2023 from cardiac arrest and blood clot in the lung.  Patient was getting heparin shots to prevent clots.  No treatment medication was provided. Company comment: This spontaneous case concerns a male patient of unknown age, with no medical history reported, who experienced unexpected serious (death, medically significant) events of cardiac arrest and pulmonary embolism which occurred after receiving a dose of mRNA-1273.222, which was the patient's unknown dose of COVID-19 vaccination schedule. Latency cannot be calculated due to vaccination date unknown. It was described that the patient went to hospital due to incontinence and died later due to pulmonary embolism and cardiac arrest. No further details regarding clinical course, any accompanying circumstances that could lead to fatality, concurrent diseases, concomitant medications and whether the patient was hospitalized due to incontinence are available in the report. Outcome of events was fatal at the time of the report. Additional information has been requested and report will be updated upon receipt of follow up information. The benefit-risk relationship of mRNA-1273.222 vaccine is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2023-737183 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-737183:Reporter's case; Reported Cause(s) of Death: Cardiac arrest; Blood clot in the lung